This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kamstrup and colleagues¹ assessed the association between elevated lipoprotein(a) and risk of myocardial infarction using data from the Copenhagen General Population Study (CGPS), the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. We believe that several limitations were not adequately addressed in their article.

Measurement of lipoprotein(a) levels in the CGPS began before the IFCC/WHO consensus on lipoprotein(a) and the SRM-2B reference reagent study² leading to adoption of lipoprotein(a) measurement as a molar particle concentration (lipoprotein[a]-P), independent of apolipoprotein(a) kringle IV type 2 repeat isoform. The values of lipoprotein(a) in the CGPS are based on an assay determining lipoprotein(a) mass and are subject to bias by apolipoprotein(a) molecular weight. Comparison with current isoform-independent molar assays confirms substantial bias with the older methods.² The generalizability of the CGPS lipoprotein(a) serum level and lipoprotein(a) population percentile data to current lipoprotein(a) molar serum assays may be . . . [Full Text of this Article]

Steven R. Jones, MD
sjones64@jhmi.edu

Roger S. Blumenthal, MD
Division of Cardiology
Johns Hopkins Hospital
Baltimore, Maryland

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup, Anne Tybjærg-Hansen, Rolf Steffensen, and Børge G. Nordestgaard
JAMA. 2009;301(22):2331-2339.
ABSTRACT | FULL TEXT  

RELATED LETTER

Lipoprotein(a) Measurement and Determining Risk of Myocardial Infarction—Reply
Pia R. Kamstrup and Børge G. Nordestgaard
JAMA. 2009;302(15):1645-1646.
EXTRACT | FULL TEXT